Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TFX05-01 in Participants With Advanced Malignancies

NCT05434299 is registered in ClinicalTrials.gov with Zhejiang Yangli Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT05434299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05434299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TFX05-01 in Participants With Advanced Malignancies
Lead sponsor
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 5, 2022
Completion date
December 31, 2025
Enrollment
36 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor